Hubbry Logo
Zoster vaccineZoster vaccineMain
Open search
Zoster vaccine
Community hub
Zoster vaccine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Zoster vaccine
Zoster vaccine
Zoster vaccine
View on Wikipedia
from Wikipedia

Zoster vaccine
Vaccine description
TargetHerpes zoster, postherpetic neuralgia, Ramsay Hunt syndrome type II
Vaccine type
  • Zostavax: attenuated
  • Shingrix: recombinant protein subunit
Clinical data
Trade namesZostavax, Shingrix
License data
Pregnancy
category
Routes of
administration
ATC code
Legal status
Legal status
Identifiers
DrugBank
ChemSpider
  • none
UNII
KEGG
  (verify)

A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus, which is also responsible for chickenpox.[8]

Shingles provokes a painful rash with blisters, and can be followed by chronic pain (postherpetic neuralgia), as well as other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination.[9]

Two zoster vaccines have been approved for use in people over 50 years old.[9] Shingrix (GSK) is a recombinant subunit vaccine which has been used in many countries since 2017.[10]

Zostavax (Merck), in use since 2006,[11] is an attenuated vaccine which consists of a larger-than-normal dose of chickenpox vaccine.[8] Unlike Shingrix, Zostavax is not suitable for people with immunosuppression or diseases that affect the immune system.[9] Zostavax was discontinued in the United States in November 2020.[12]

Shingrix appears to prevent more cases of shingles than Zostavax, although side effects seem to be more frequent.[10][13]

Another vaccine, known as varicella vaccine, is used to prevent diseases caused by the same virus.[14]

Medical uses

[edit]

Zoster vaccination is used to prevent shingles and its complications, including postherpetic neuralgia.[8][9] It can be considered a therapeutic vaccine, given that it is used to treat a latent virus that has remained dormant in cells since chicken pox infection earlier in life.[8] The available zoster vaccine is intended for use in people over the age of 50.[9] As of 2021 it was not confirmed whether a booster dose was required,[15][10] but the Advisory Committee on Immunization Practices (ACIP) in the United States recommends Shingrix for adults over the age of 50, including those who have already received Zostavax.[16]

Shingrix

[edit]
Shingrix

The ACIP voted that Shingrix is preferred over Zostavax for the prevention of zoster and related complications because data showed vaccine efficacy of more than 90% against shingles across all age groups. Unlike Zostavax[17], which is given as a single shot, Shingrix[18] is given as two identical intramuscular doses, two to six months apart.[16][11][19] Shingrix provides high levels of immunity for at least 7 years after vaccination, but it is possible the vaccine may provide protection for much longer.[20][21]

A large randomized clinical trial[which?] showed Shingrix reduced the incidence of shingles 96.6% (relative risk reduction, RRR) in the 50–59 age group, and 91.3% (relative risk reduction, RRR) in those over age 70.[citation needed] The absolute decrease in risk (absolute risk reduction, ARR) of herpes zoster following immunization over three and a half years is 3.3% (3.54% down to 0.28%) while the decrease in the risk of postherpetic neuralgia is 0.3% (0.34% down to 0.06%).[22][23][24]

Zostavax

[edit]
Zostavax vaccine

The Zostavax vaccine (both single dose and two-dose regime) is likely effective at protecting people from herpes zoster disease for a duration of up to three years.[25] The degree of longer term protection (beyond 4 years from the initial vaccination) is not clear. The need for re-vaccination after the first full vaccine schedule is complete remains to be confirmed.[25]

Zostavax was shown to reduce the incidence of shingles by 51% in a study of 38,000 adults aged 60 and older who received the vaccine. The vaccine also reduced by 67% the number of cases of postherpetic neuralgia (PHN) and reduced the severity and duration of pain and discomfort associated with shingles, by 61%.[26][27][4] The FDA originally recommended it for individuals 60 years of age or older who are not severely allergic to any of its components and who meet the following requirements:[28][29]

In 2006, the US Advisory Committee on Immunization Practices (ACIP) recommended that the live vaccine be given to all adults age 60 and over, including those who have had a previous episode of shingles,[30] and those who do not recall having had chickenpox, since more than 99% of Americans ages 40 and older have had chickenpox.[20]


Side effects

[edit]

Shingrix

[edit]

Temporary side effects from the Shingrix shots are likely and can be severe enough in one out of six people to affect normal daily activities for up to three days.[20] Mild to moderate pain at the injection site is common, and some may have redness or swelling.[20] Side effects include fatigue, muscle pain, headache, shivering, fever, and nausea.[20] Symptoms usually resolve in two to three days.[20] Side effects with Shingrix are greater than those with Zostavax and occur more frequently in individuals aged 50 to 69 years compared with those 70 years and older.[10][5]

Zostavax

[edit]

The live vaccine (Zostavax) is very safe; one to a few percent of people develop a mild form of chickenpox, often with about five or six blisters around the injection site, and without fever. The blisters are harmless and temporary.[31][32] In one study 64% of the Zostavax group and 14% of the controls had some adverse reaction. However, the rates of serious adverse events were comparable between the Zostavax group (0.6%) and those receiving the placebo (0.5%).[33] A study including children with leukaemia found that the risk of getting shingles after vaccination is much lower than the risk of getting shingles for children with natural chicken pox in their history. Data from healthy children and adults point in the same direction.[31]

Zostavax is not used in people with compromised immune function.[34][35]

Composition

[edit]

Shingrix

[edit]

Shingrix is a suspension for intramuscular injection consisting of a lyophilized recombinant varicella zoster virus glycoprotein E antigen that is reconstituted at the time of use with AS01B suspension as an immunological adjuvant. The antigen is a purified truncated form of the glycoprotein, expressed in Chinese hamster ovary cells. The AS01B adjuvant suspension is composed of 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella (Minnesota strain) and a saponin molecule (QS-21) purified from Quillaja saponaria (soap bark tree) extract, combined in a liposomal formulation consisting of dioleoyl phosphatidylcholine (DOPC) and cholesterol in phosphate-buffered saline solution.[36]

Zostavax

[edit]

Zostavax contains live attenuated varicella-zoster virus.[31][12] It is injected subcutaneously (under the skin) in the upper arm.[37] The live vaccine is produced using the MRC-5 line of fetal cells.[4] This has raised religious and ethical concerns for some potential users, since that cell line was derived from an aborted fetus.[38]

Cost effectiveness

[edit]

A 2007 study found that the live vaccine is likely to be cost-effective in the US, projecting an annual savings of US$82 to US$103 million in healthcare costs with cost-effectiveness ratios ranging from US$16,229 to US$27,609 per quality-adjusted life year gained.[39] In 2007, the live vaccine was officially recommended in the US for healthy adults aged 60 and over, but is no longer given out in the United States as of 2020, given the superiority of Shingrix.[40][41][42]

In Canada the cost of Shingrix is about CA$300 for the two doses.[22] This likely represents a more cost effective intervention than the live vaccine given its lower cost and increased effectiveness.[43]

History

[edit]

European Union

[edit]

In 2006, the European Medicines Agency (EMA) issued a marketing authorization for the zoster vaccine to Sanofi Pasteur for routine vaccination in individuals aged 60 and over.[44][6] In 2007, the EMA updated the marketing authorization for routine vaccination in individuals aged 50 and over.[45][6]

Shingrix was approved for medical use in the European Union in March 2018, with an indication for the prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN) in adults 50 years of age or older.[7]

United Kingdom

[edit]

From 2013, the UK National Health Service (NHS) started offering shingles vaccination to elderly people. People aged either 70 or 79 on 1 September 2013, were offered the vaccine. People aged 71 to 78 on that date would only have an opportunity to have the shingles vaccine after reaching the age of 79.[46] The original intention was for people aged between 70 and 79 to be vaccinated, but the NHS later said that the vaccination program was being staggered as it would be impractical to vaccinate everyone in their 70s in a single year.[47]

In 2021, vaccination against shingles is available on the NHS to people aged 70 to 79.[48] Vaccination is with single-dose Zostavax, except for people for whom Zostavax is deemed unsuitable, for example, with a condition that affects the immune system, for whom two-dose Shingrix vaccine is recommended.[48] The NHS stated "The shingles vaccine is not available on the NHS to anyone aged 80 or over because it seems to be less effective in this age group".[48] Since 2023, the shingles vaccines is being offered to healthy people turning 65.[49]

[edit]

Researchers analyzing the health records of Welsh older adults discovered that those who received the shingles vaccine (specifically, Zostavax) were 20% less likely to develop dementia over the next seven years than those who did not receive the vaccine.[50]

United States

[edit]

Zostavax was developed by Merck & Co. and approved and licensed by the US Food and Drug Administration (FDA) in May 2006,[26] In 2011, the FDA approved the live vaccine for use in individuals 50 to 59 years of age.[4][51] Shingrix is a zoster vaccine developed by GlaxoSmithKline that was approved in the United States in October 2017.[52] Shingrix, which provides strong protection against shingles and PHN, was preferred over Zostavax before Zostavax was discontinued.[53]

In June 2020, Merck discontinued the sale of Zostavax in the US. Vaccine doses already held by practitioners could still be administered up to the expiration date (none expired later than November 2020).[54][12]

The US Centers for Disease Control and Prevention (CDC) recommends that healthy adults 50 years and older get two doses of Shingrix, at least two months apart. Initial clinical trials only tested a gap of less than six months between doses, but unexpected popularity and resulting shortages caused further testing to validate wider spacing of the two doses.[55][56] Adults 19 years and older who are immunocompromised because of disease or therapy are also recommended to receive two doses of Shingrix.[20]

The zoster vaccine is covered by Medicare Part D. In 2019, more than 90% of Medicare Part D vaccine spending was for the zoster vaccine. 5.8 million vaccine doses were administered to Part D beneficiaries that year at a cost of $857 million.[57]

References

[edit]

Further reading

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Zoster vaccine

View on Grokipedia
from Grokipedia
The zoster vaccine comprises immunizations designed to prevent , a dermatomal rash with blisters and resulting from reactivation of latent varicella-zoster virus in sensory ganglia of previously infected individuals. Two principal formulations exist: Zostavax, a approved by the FDA in 2006 with efficacy ranging from 51% to 67% against in adults aged 50 years and older, which wanes over time; and Shingrix, a recombinant E adjuvanted with AS01B, approved in 2017, demonstrating vaccine efficacy of 97.2% (95% CI: 93.7-99.0) against in the pivotal ZOE-50 trial for immunocompetent adults aged 50 and older. Shingrix maintains robust protection, with efficacy of 91.3% (95% CI: 86.8-94.5) in those aged 70 and older from the ZOE-70 trial, and is recommended by the CDC as a two-dose series for adults aged 50 years and older, including those previously vaccinated with Zostavax, due to its superior immunogenicity and durability. Shingrix has been extended to immunocompromised adults aged 19 and older, showing 68.2% efficacy against herpes zoster in conditions like hematologic malignancies, with benefits extending to prevention of , a debilitating syndrome occurring in up to 20% of unvaccinated cases. Real-world studies confirm sustained effectiveness, with two doses yielding 70.1% protection against herpes zoster in older adults. Safety profiles indicate common reactogenicity such as injection-site pain, , and resolving within days, though rare serious adverse events include Guillain-Barré syndrome, prompting an FDA update based on post-marketing estimating an excess risk of approximately three cases per million doses. Empirical data from large-scale trials and observational cohorts affirm that the vaccine's benefits in averting herpes zoster and its sequelae substantially outweigh these infrequent risks, particularly given the rising incidence of with population aging.

Background

Herpes Zoster and Postherpetic Neuralgia

Herpes zoster, also known as , arises from reactivation of the latent varicella-zoster virus (VZV) in cranial or dorsal root ganglia following primary infection as varicella (). Individuals without prior varicella infection do not harbor latent VZV and thus cannot develop shingles via reactivation, rendering zoster vaccination unnecessary in such cases. The virus, a human alphaherpesvirus, establishes lifelong latency in sensory neurons after initial dissemination via T cells and skin lesions during childhood infection. Reactivation occurs when cell-mediated immunity declines, allowing viral replication in neurons and spread to the skin, producing unilateral vesicular eruption along a dermatome accompanied by acute from and . In the United States, lifetime risk of zoster is approximately 30-33%, with about 50% of individuals aged 85 years or older affected. Annual incidence ranges from 2 to 9 cases per 1,000 population, rising sharply with age: rates are under 2 per 1,000 in those under 50 but exceed 10 per 1,000 in those over 80. Primary risk factors include advanced age due to , from conditions like , , , or use, and prior varicella ; other associations include female sex and certain psychological stressors, though causation remains correlative. Postherpetic neuralgia (PHN), the most severe complication of herpes zoster, is defined as dermatomal persisting beyond 90 days after onset, resulting from persistent neuronal damage and central sensitization. PHN develops in 10-18% of all herpes zoster cases, with incidence increasing to 20-30% in patients over 70 years due to age-related vulnerability in processing pathways. is typically burning, stabbing, or allodynic, lasting months to years in many cases—up to a median of 1 year or longer in severe instances—and associated with substantial morbidity, including sleep disruption, depressive disorders, reduced mobility, and diminished comparable to impacts from congestive or depression.

Rationale for Zoster Vaccination

Herpes zoster, commonly known as , arises from the reactivation of latent varicella-zoster virus (VZV) in sensory ganglia following primary infection with varicella (), a process driven by an age-related decline in VZV-specific (CMI). This waning of CMI, rather than persistent high-level , permits viral , as natural infection establishes latency but fails to confer indefinite protection against reactivation, contradicting notions of lifelong immunity post-. Empirical observations confirm that VZV-specific T-cell responses diminish progressively from onward, with reactivation rates escalating sharply after age 50 due to , independent of exogenous reinfection. The disease burden underscores the imperative for preventive strategies beyond reactive measures. In the United States, approximately 1 million herpes zoster episodes occur annually, affecting about one in three individuals over their lifetime, predominantly those aged 50 and older. This translates to substantial healthcare utilization, with direct medical costs per episode ranging from $1,000 to over $3,000 and aggregate annual expenditures for complications exceeding $2 billion, including productivity losses from pain-induced immobility and reduced in the elderly. (PHN), the most debilitating sequela, persists in 10-18% of cases, impairing daily function and amplifying indirect societal costs through long-term disability. Antiviral therapies, such as acyclovir or valacyclovir, mitigate acute and duration when administered early but do not substantively avert PHN or fully address reactivation's root cause of deficient CMI. High-quality evidence from randomized trials indicates no significant reduction in PHN incidence with antivirals alone ( around 0.75-1.0 at four months), as they target lytic replication post-onset rather than prophylactically reinforcing T-cell surveillance against latency. Consequently, emerges as a causal intervention to augment targeted CMI components, such as those against key viral glycoproteins, thereby interrupting the pathway from immunologic attrition to clinical disease in vulnerable populations.

Vaccine Types and Characteristics

Recombinant Zoster Vaccine (Shingrix)

The recombinant zoster vaccine, Shingrix, is a non-live subunit vaccine comprising recombinant varicella-zoster virus (VZV) glycoprotein E (gE) antigen produced in Chinese hamster ovary cells, adjuvanted with AS01B, a liposome-based system containing monophosphoryl lipid A (MPL) and QS-21. This formulation targets the gE protein, a key envelope glycoprotein essential for VZV cell attachment and fusion, without incorporating the live virus. Shingrix received U.S. (FDA) approval on October 20, 2017, for adults aged 50 years and older. The authorized its marketing on March 21, 2018, following positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. It is administered intramuscularly as a two-dose regimen, with the second dose given 2 to 6 months after the first. In contrast, the predecessor live-attenuated Zostavax vaccine, based on the Oka strain of VZV, was licensed in 2006 but discontinued due to waning durability of and manufacturing supply constraints. Merck ceased U.S. sales of Zostavax in June 2020, with existing stocks usable until expiration, and fully discontinued production by November 2020. In the , its marketing authorization was withdrawn effective June 1, 2025, after the marketing authorization holder's decision not to pursue renewal amid low demand. These developments positioned Shingrix as the dominant option, supplanting Zostavax through its non-replicating design suitable for broader populations, including those with contraindications to live vaccines.

Live Attenuated Zoster Vaccine (Zostavax)

![Zostavax vaccine vial](./assets/ZOSTAVAX_shingles(herpeszostershingles_(herpes_zoster) Zostavax is a live attenuated vaccine containing the Oka/Merck strain of varicella-zoster virus, administered as a single subcutaneous dose of approximately 0.65 mL. It was indicated for the prevention of herpes zoster in immunocompetent individuals aged 50 years and older, though the U.S. Centers for Disease Control and Prevention (CDC) recommended its use starting at age 60. Due to its live virus composition, Zostavax was contraindicated in immunocompromised persons, including those with primary or acquired immunodeficiencies or receiving immunosuppressive therapy, owing to the risk of vaccine-strain virus dissemination and severe infection. The vaccine was not approved or recommended for children or varicella-naive individuals, as it is not a substitute for the varicella vaccine (Varivax) and could potentially cause a varicella-like illness in those without prior exposure. Introduced in 2006 following the widespread adoption of childhood varicella vaccination in the mid-1990s, Zostavax served to boost waning cell-mediated immunity against latent varicella-zoster virus in older adults, addressing the persistent risk of zoster reactivation despite reduced circulating wild-type virus. Merck discontinued U.S. sales of Zostavax in June 2020, with the vaccine becoming unavailable after November 18, 2020, as existing stockpiles expired. This phase-out reflected a shift toward recombinant non-live alternatives like Shingrix, driven by Zostavax's limitations including time-limited protection, contraindications in vulnerable populations, and lower overall adoption amid superior options. Globally, marketing authorizations followed suit, with the European Union withdrawing approval on June 1, 2025. As a legacy intervention, Zostavax provided a temporary bridge in zoster prevention strategies during the transition to broader-spectrum vaccines, though its role diminished with evidence favoring non-live formulations for sustained public health impact.

Indications and Efficacy

Efficacy Against Herpes Zoster and Complications

The recombinant zoster vaccine (Shingrix) demonstrated 97.2% efficacy against herpes zoster in adults aged 50 years and older in the ZOE-50 , which enrolled over 15,000 participants and followed them for a of 3.2 years. In the ZOE-70 trial involving adults aged 70 years and older, efficacy against herpes zoster was 89.8%, with pooled analyses from both trials confirming sustained high protection across age subgroups within these cohorts. These results were derived from confirmed cases via or clinical adjudication, highlighting the vaccine's robust prevention of varicella-zoster virus reactivation. For , a key complication of herpes zoster defined as pain persisting beyond 90 days, Shingrix showed over 90% efficacy in reducing incidence among adults aged 50 years and older, with pooled ZOE-50 and ZOE-70 data indicating 91.2% protection overall and 88.8% in those aged 70 and older. This reduction stems from the vaccine's impact on lowering herpes zoster occurrence, as primarily affects breakthrough cases, though direct prevention of neuralgia severity in such instances was not separately quantified in primary trial endpoints. The live attenuated zoster vaccine (Zostavax) exhibited 51.3% efficacy against zoster in the Prevention Study, a randomized of over 38,000 adults aged 60 years and older followed for up to 4.2 years post-vaccination. varied by age, reaching 63.9% in those aged 60-69 years but declining to 37.6% in those 70 years and older, based on confirmed cases meeting clinical and laboratory criteria. Against in breakthrough zoster cases, Zostavax reduced risk by 66.5%, reflecting its partial attenuation of viral load and inflammation duration.
VaccineTrialPopulationHZ Efficacy (%)PHN Efficacy (%)
ShingrixZOE-50≥50 years97.2>90 (pooled)
ShingrixZOE-70≥70 years89.888.8 (pooled)
ZostavaxSPS≥60 years51.366.5

Long-Term Effectiveness and Waning

The recombinant zoster vaccine (RZV; Shingrix) exhibits high durability of protection against herpes zoster (HZ), with minimal evidence of waning over extended periods. In the final analysis of the ZOE-LTFU trial, which followed participants from the original ZOE-50/70 studies for up to 11 years post-vaccination, RZV maintained 79.7% (95% CI: 73.7–84.6) against HZ in adults aged ≥50 years during years 6–11. This sustained effectiveness, observed across age subgroups including those ≥70 years, supports projections of protection lasting at least a or more, contrasting with expectations of age-related immune decline. In comparison, the live attenuated zoster vaccine (ZVL; Zostavax) shows rapid waning, with effectiveness against HZ dropping from 67% (95% CI: 65–69%) in the first year to 47% in the second year and further to 15% (95% CI: 5–24%) after 10 years in adults aged ≥50 years. Among those ≥70 years, declined by approximately 50% by the third year post-, contributing to its discontinuation in favor of RZV in vaccination guidelines due to inadequate long-term protection. These differences in persistence stem from distinct immunological profiles: RZV's AS01B adjuvant enhances and sustains + T-cell responses targeting glycoprotein E, promoting polyfunctional memory T cells that control varicella-zoster over time, whereas ZVL's reliance on live virus replication yields that wanes more precipitously with age. Long-term data confirm RZV's superior maintenance of gE-specific + T-cell frequencies beyond one year, correlating with observed clinical durability.

Real-World Performance Data

Post-marketing surveillance from U.S. Medicare databases and European health registries has shown the recombinant zoster vaccine (RZV; Shingrix) to exhibit 70-85% against herpes zoster (HZ) in adults aged 50 years and older, lower than peak trial estimates due to inclusion of frailer and comorbid populations in real-world cohorts. A 2025 analysis of over 3 million Medicare enrollees confirmed RZV's real-world under routine conditions, with two doses yielding approximately 74% protection against HZ incidence. HZ rates are notably higher among frail elderly subgroups, estimated at 10-15%, reflecting diminished immune responses in those with and reduced functional status. In contrast, real-world data for the live attenuated zoster vaccine (Zostavax) indicate initial effectiveness of around 40-50% against HZ, with more pronounced waning over time—dropping to 41% against after 10 years in population-based studies. Uptake of Zostavax remained suboptimal prior to its 2020 discontinuation, with coverage below 30% among eligible U.S. adults aged 60 and older in 2018. Empirical observations highlight further reductions in vaccine effectiveness among immunocompromised individuals, typically 10-20% lower than in immunocompetent groups, attributable to underlying immune deficits rather than vaccine failure per se; meta-analyses report pooled VE of about 65% in such populations. No consistent evidence from surveillance data supports benefits from zoster vaccination, as HZ reactivation does not substantially drive community transmission of varicella-zoster virus, and adult exposure patterns remain unchanged post-vaccination rollout.
VaccineReal-World VE Against HZ (Adults ≥50 Years)Key Limitations Observed
Shingrix (RZV)70-85% overall; ~74% in Medicare cohortsHigher breakthroughs (10-15%) in frail elderly; 10-20% lower in immunocompromised
Zostavax40-50% initial; wanes to ~40% at 10 yearsRapid waning; low uptake (<30% pre-2020)

Administration and Usage

Dosing Schedules and Recommendations

The recombinant zoster vaccine (Shingrix) is administered in two doses of 0.5 mL each via , with the second dose given 2 to 6 months after the first. The Centers for Disease Control and Prevention (CDC) and Advisory Committee on Practices (ACIP) specify this schedule as standard for eligible adults. The live attenuated zoster vaccine (Zostavax), now discontinued since 2020, was historically administered as a single 0.65 mL dose via subcutaneous injection in the deltoid region of the upper arm. Zostavax is not interchangeable with Shingrix, and prior receipt of Zostavax does not alter the two-dose Shingrix schedule.
VaccineDose VolumeRouteSchedule
Shingrix0.5 mLIntramuscularTwo doses, 2–6 months apart
Zostavax (historical)0.65 mLSubcutaneousSingle dose
As of 2025, no routine booster doses are recommended for Shingrix following the primary two-dose series, pending further long-term data on durability. The aligns with a similar two-dose regimen for Shingrix in adults aged 50 years and older.

Special Populations and Timing

The recombinant zoster vaccine (Shingrix) is recommended for immunocompromised adults aged 19 years and older, including those with , hematologic malignancies, solid tumors, solid organ transplants, or hematopoietic stem cell transplants, to prevent herpes zoster and complications, whereas the live attenuated Zostavax is contraindicated in this population due to the risk of vaccine-strain dissemination. For hematopoietic stem cell transplant recipients, Shingrix dosing typically begins 50–70 days post-autologous transplant or later for allogeneic transplants once immunosuppression stabilizes, with studies demonstrating robust immunogenicity when administered shortly after engraftment to mitigate early zoster risk. Solid organ transplant patients may receive Shingrix starting 3–6 months post-transplant if clinically stable, balancing immunosuppression levels against heightened zoster susceptibility. Individuals with a prior herpes zoster episode can receive Shingrix once the resolves, with no mandatory CDC-specified delay, though observational data suggest optimal if vaccinated 6–12 months post-episode to avoid interference from residual natural immunity. Immunocompetent patients may benefit from a 12-month wait to leverage boosted natural responses, while immunocompromised individuals can proceed from 3 months post-resolution. In 2025, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion for a prefilled presentation of Shingrix, anticipated for full approval in December, facilitating easier administration and reduced preparation errors in frail elderly or immunocompromised patients unable to handle reconstitution. This innovation addresses logistical barriers in special populations with dexterity or cognitive impairments, building on the U.S. FDA's July 2025 approval of the same format.

Safety and Adverse Effects

Common Local and Systemic Reactions

The recombinant zoster vaccine (Shingrix) exhibits higher reactogenicity than the live attenuated vaccine (Zostavax), with solicited local reactions occurring in approximately 82% of recipients within 7 days post-dose, primarily injection-site pain affecting 79%, alongside redness and swelling in 38% and 26%, respectively. Systemic reactions affect about 66% of recipients, including (46%), (45%), (38%), (27%), and fever (21%), with most events mild to moderate and resolving within a of 1-3 days. Grade 3 (severe) reactions, preventing normal daily activities, occur in 17% overall, more frequently after the second dose. In contrast, Zostavax elicits milder responses, with injection-site reactions in 35-64% of recipients depending on age group, manifesting as pain/tenderness (35%), (34%), or swelling (26%), and systemic events like in 9%. These are generally self-limited, with lower overall incidence than Shingrix, though or pruritus at the site can occur in up to 10%. Vaccine-related dissemination manifesting as mild varicella-like happens in fewer than 1% but warrants monitoring in immunocompromised individuals. Management of these common reactions for both vaccines involves symptomatic relief with over-the-counter analgesics such as acetaminophen or ibuprofen, rest, and hydration, as no routine prophylaxis is recommended prior to . Trial discontinuation due to adverse reactions remains low at under 1% for Shingrix, indicating tolerability despite higher frequency.

Serious Risks Including Guillain-Barré Syndrome

Postmarketing surveillance through systems like VAERS has identified rare reports of Guillain-Barré syndrome (GBS) temporally associated with Zostavax administration, but large-scale observational studies and clinical trials have not demonstrated an attributable excess risk beyond background population rates of approximately 1-2 cases per 100,000 annually. In contrast to findings with recombinant zoster vaccines, no statistically significant elevated incidence of GBS was observed in Zostavax recipients during post-approval monitoring from 2006 onward, with causality remaining unestablished for reported cases due to the self-reported nature of VAERS data and factors like age-related baseline risks. For the recombinant zoster vaccine (Shingrix), observational data in older adults have shown a small increased risk of GBS, estimated at 3 excess cases per million doses overall, with approximately 6 excess cases per million after the first dose and no increased risk after the second dose; this association, while not definitively proving causality, led to an FDA-required warning in the prescribing information. Other serious adverse events reported post-Zostavax include , occurring at rates estimated below 1 per 100,000 doses based on vaccine data, manifesting as reactions requiring immediate intervention. No verified causal links to fatalities have been confirmed in regulatory reviews or peer-reviewed analyses, with reported deaths in VAERS typically attributable to comorbidities in elderly recipients rather than the vaccine itself. Claims of myocarditis or other inflammatory cardiac events lack substantiation in controlled studies or FDA monitoring specific to Zostavax. For individuals aged 50 years and older—the primary target group—efficacy in preventing herpes zoster and its complications generally outweighs these rare serious risks, as evidenced by net reductions in from clinical and real-world data. However, caution is advised for those with prior neurological conditions, including history of GBS, where providers should weigh individual risk profiles, though no specific Zostavax-attributable exists beyond general precautions.

Comparative Safety Profiles

The recombinant zoster vaccine (Shingrix, RZV) exhibits higher rates of short-term reactogenicity compared to the live attenuated zoster vaccine (Zostavax, ZVL), with clinical trials reporting grade 3 or higher local reactions (e.g., injection-site ) in 17-21% of RZV recipients versus 0-1% for ZVL, and systemic reactions (e.g., , ) in 9-17% versus 1-4%. These RZV-associated events typically resolve within 2-3 days and do not lead to increased discontinuation rates in head-to-head assessments. In contrast, ZVL carries inherent risks from its live Oka strain varicella-zoster virus, including rare instances of vaccine-strain herpes zoster , particularly in vulnerable populations, with post-licensure documenting cases of vaccine-associated and, in immunocompromised individuals, potential for severe . RZV, being non-live, eliminates this dissemination risk, enabling its use in a broader range of adults, including many previously contraindicated for ZVL due to (e.g., those on moderate-dose corticosteroids or certain chemotherapies). ZVL is contraindicated in the majority of immunocompromised adults—estimated to represent over 50% of such cases based on common immunosuppressive conditions—due to the potential for vaccine-induced , whereas RZV's acellular formulation supports its recommendation in select immunocompromised groups aged 19 and older, with no evidence of increased serious adverse events in these cohorts relative to immunocompetent recipients. Post-2020 recommendations prioritizing RZV over ZVL, culminating in ZVL's U.S. discontinuation by March 2020, have correlated with reduced reports of ZVL-attributable dissemination events in data, without emergent safety signals for RZV beyond known reactogenicity.

Contraindications and Precautions

Absolute and Relative Contraindications

Shingrix (recombinant zoster vaccine): Absolute contraindications are limited to a history of severe allergic reaction, such as , to any component of the (including E , AS01B adjuvant containing MPL and QS-21, or lipids) or following a prior dose of Shingrix. As a non-live , Shingrix lacks contraindications associated with or related to risks. Shingrix may be administered to patients receiving prophylactic antiviral therapy, such as acyclovir, without known contraindications or interactions requiring interruption of therapy, as these agents do not affect the immunogenicity of the non-live recombinant vaccine; this contrasts with live attenuated zoster vaccines like Zostavax, where antivirals may inhibit vaccine virus replication. Relative contraindications include active, untreated zoster, where should be deferred until the rash resolves to avoid potential interference with or diagnostic confusion, and moderate or severe acute illness with or without fever, which warrants postponement until recovery to minimize confounding symptoms or reduced . Pre-existing peripheral neuropathy unrelated to Guillain-Barré syndrome is not a contraindication; Shingrix is recommended for adults aged 50 years and older with such conditions, as the benefits in preventing herpes zoster—which can exacerbate neuropathy via postherpetic neuralgia—outweigh rare risks, per CDC guidelines and expert guidance. Zostavax (zoster vaccine live): Absolute contraindications encompass to any component, such as neomycin or ; primary or acquired states (e.g., congenital or acquired , with CD4 <200 cells/mm³, or hematologic/ solid malignancies affecting cellular immunity); active immunosuppressive therapy (e.g., high-dose systemic corticosteroids equivalent to ≥20 mg/day for ≥2 weeks, alkylating agents, antimetabolites, , or TNF blockers); and , due to the live attenuated varicella-zoster virus risk of fetal transmission akin to wild-type virus. Relative contraindications include recent receipt of antibody-containing blood products (e.g., immunoglobulin or plasma within 5 months), which may interfere with replication and , requiring deferral; active, untreated zoster; and moderate or severe acute illness, similar to Shingrix guidelines. Zostavax is no longer available in the United States since November 2020, limiting its clinical relevance to prior recipients or international contexts.

Interactions and Monitoring

Recombinant zoster vaccine (Shingrix) can be co-administered with other adult vaccines, including influenza and pneumococcal vaccines, at different anatomic sites without evidence of immune interference or reduced efficacy for either vaccine. Post-marketing studies have confirmed that co-administration with inactivated influenza vaccines does not significantly alter reactogenicity, immunogenicity, or safety profiles compared to separate administration. Similarly, co-administration with pneumococcal polysaccharide vaccine (PPSV23) shows no interference in antibody responses to Shingrix antigens. In frail or immunocompromised individuals, providers may counsel patients on potential increased local reactogenicity from concurrent use with other adjuvanted vaccines, though data support safety; separation by at least 4 weeks may be considered if patient tolerance is a concern, but is not required. Post-vaccination monitoring for Shingrix focuses on reporting potential serious adverse events, particularly Guillain-Barré syndrome (GBS), with an observed increased risk during the 42 days following each dose. Patients should be advised to seek immediate medical attention for GBS symptoms such as progressive , tingling, or difficulty walking within this 42-day window, as observational studies estimate an excess risk of approximately 3 GBS cases per million doses administered. No routine laboratory testing is recommended prior to except in high-risk cases with specific contraindications; standard post-vaccination follow-up involves for common reactions like injection-site pain, which typically resolve within days. For inadvertent Shingrix exposure during , data are limited and insufficient to confirm vaccine-associated risks, with no ACIP recommendation for use in pregnant individuals; providers should delay until postpartum and offer counseling on the lack of established fetal from recombinant components, based on animal developmental studies showing no adverse effects at doses exceeding equivalents. Zostavax, a live no longer available since 2020, required monitoring for vaccine-related rash, which should be covered to prevent transmission of attenuated , though such interactions are not applicable to current recombinant formulations.

Composition and Mechanism of Action

Shingrix Formulation and Immunology

Shingrix is a recombinant subunit vaccine composed of 50 micrograms of purified glycoprotein E (gE) antigen derived from varicella-zoster virus (VZV), lyophilized and reconstituted with an AS01B adjuvant suspension prior to intramuscular administration. The AS01B adjuvant system includes the Toll-like receptor 4 agonist 3-O-desacyl-4'-monophosphoryl lipid A (MPL) from Salmonella minnesota, the saponin QS-21 from Quillaja saponaria tree bark, cholesterol, and 3-O-desacyl-4'-monophosphoryl lipid A in a squalene-in-water emulsion, which enhances antigen presentation and immune activation. Additional excipients in the formulation include sucrose, polysorbate 80, sodium dihydrogen phosphate dihydrate, and disodium phosphate anhydrous for stabilization and buffering. The vaccine's recombinant design targets gE, a key essential for VZV cell-to-cell spread and a dominant target of cellular immunity during natural , without incorporating live or other viral proteins. Upon administration, Shingrix elicits a potent, polyfunctional dominated by gE-specific + T cells, which exhibit effector functions such as interferon-γ production, , and CD40 ligand expression, alongside robust anti-gE antibody titers. This + T cell response, often exceeding a 10-fold increase in frequency post-vaccination, recruits both memory and naive T cells, contributing to long-term persistence that counters age-related in VZV-specific immunity. The adjuvant-driven mechanism mimics aspects of viral reactivation by amplifying T helper 1-biased responses critical for controlling latent VZV in sensory ganglia, without inducing herpes zoster disease. The two-dose regimen, administered intramuscularly two to six months apart, is required for optimal priming and boosting of this cellular and , as a single dose yields inferior durability. For stability, unreconstituted vials must be stored refrigerated at 2–8°C (36–46°F) with a of up to 36 months from manufacture, protected from light and freezing; post-reconstitution, the suspension should be used immediately or held refrigerated for no more than six hours.

Zostavax Formulation and Immunology

Zostavax consists of a lyophilized preparation of live, attenuated (VZV) from the Oka/Merck strain, reconstituted with sterile prior to in a single 0.65 mL dose. Each dose contains a minimum of 19,400 plaque-forming units (PFU) of the , approximately 14 times the potency of the Varivax, which has a minimum of 1,350 PFU. The formulation includes excipients such as , hydrolyzed porcine , , and trace amounts of neomycin to stabilize the and prevent bacterial contamination. As a live , Zostavax induces immunity through limited replication in the host, mimicking aspects of natural VZV infection to stimulate both humoral and cellular responses. It primarily boosts VZV-specific antibody production and + T-cell responses, including expansion of T cells recognizing multiple VZV open reading frames, though the augmentation of T-cell breadth and persistence is constrained relative to subunit s with potent adjuvants. The vaccine virus establishes latency but exerts minimal interference with wild-type VZV reactivation from sensory ganglia, relying instead on enhanced host immunity to reduce zoster incidence. Key limitations stem from its live-virus nature: the formulation is temperature-sensitive, necessitating frozen storage at or below -15°C for stability, with post-thaw requirements that complicate . Additionally, while reduces , rare potential exists for viral reversion or , as evidenced by isolated cases of herpes zoster caused by the vaccine-derived Oka strain in immunocompetent individuals.

Broader Health Associations

Observational studies have linked herpes zoster vaccination to reduced incidence, primarily attributing this to prevention of varicella-zoster virus (VZV) reactivation, which may trigger implicated in cognitive decline. A 2025 using electronic health records from over 200,000 older adults in found that Zostavax vaccination reduced the probability of a new by 3.5 percentage points (absolute risk reduction) over 7 years, corresponding to a 20% compared to unvaccinated individuals, with analyses designed to minimize through quasi-random assignment based on vaccination policies. Similarly, U.S. cohort data from 2024-2025 indicate that recombinant zoster vaccine (Shingrix) administration correlates with a 17-24% lower risk over 3-6 years post-vaccination, outperforming Zostavax by 17% in head-to-head comparisons within the same populations. The association appears stronger for subtypes, with reductions up to 50% relative to other vaccines like pneumococcal, though absolute effects remain modest at around 3-5% over follow-up periods. Proposed mechanisms center on the herpes virus-dementia hypothesis, where subclinical VZV reactivation in sensory ganglia leads to peripheral immune activation and central nervous system inflammation, potentially priming microglia and accelerating amyloid-beta or tau pathology in susceptible aging brains. Vaccination mitigates this by boosting VZV-specific T-cell immunity, reducing reactivation frequency and associated inflammatory cascades, as evidenced by lower post-vaccination VZV DNA detection in neural tissues and attenuated microglial hyperactivation in preclinical models. This effect holds for both live-attenuated Zostavax and adjuvanted Shingrix, but the latter's AS01 adjuvant elicits a more robust, durable cellular response, potentially amplifying neuroprotection against chronic VZV-driven stressors. Despite consistency across datasets from the and U.S., these findings derive from observational designs without randomized controlled trials (RCTs), limiting . Potential confounders include the healthy vaccinee effect, wherein healthier individuals are more likely to receive , though natural experiment approaches partially address this by exploiting exogenous variation in access. No RCTs have directly tested endpoints, and residual biases from unmeasured factors like or baseline persist, underscoring the need for prospective trials to confirm causality beyond associative evidence.

Potential Cardiovascular and Mortality Benefits

A 2025 systematic review and presented at the Congress found that herpes zoster vaccination was associated with an 18% lower risk of or in adults aged 18 and older, with a 16% reduction observed specifically among those under 65. This aligns with earlier observational data indicating up to a 23% reduction in composite cardiovascular events, including , heart failure, and coronary heart disease, sustained for up to eight years post-vaccination. Herpes zoster itself acts as a proinflammatory trigger, releasing cytokines that promote endovascular and atherosclerotic plaque instability, thereby elevating short-term risks of (MACE). Vaccination mitigates this by preventing reactivation, with studies showing dose-response patterns where higher vaccine coverage correlates with fewer post-HZ cardiovascular complications. Data from IDWeek 2025 presentations further indicate that zoster vaccination in adults aged 50 and older is linked to reduced all-cause mortality, alongside lower incidences of heart disease, independent of episodes. These mortality benefits appear durable, extending beyond 7–10 years in cohort analyses, though primarily derived from observational designs tracking vaccinated versus unvaccinated populations. Causality remains debated, as associations persist across varying herpes zoster incidence rates, suggesting potential direct immunomodulatory effects beyond mere infection prevention; however, randomized trials are lacking, and benefits may be attenuated in low-prevalence regions where baseline risks are minimal. Critics note that confounding factors, such as healthier vaccine recipients, could inflate estimates, underscoring the need for causal inference methods like propensity matching in future research.

Cost-Effectiveness and Access

Economic Analyses and Value Assessments

Economic modeling of recombinant zoster vaccine (RZV, Shingrix) in the United States has demonstrated incremental cost-effectiveness ratios (ICERs) ranging from approximately $22,000 to $37,000 per (QALY) gained, depending on age cohorts and assumptions about zoster (HZ) incidence and vaccine efficacy duration. For adults aged 50 years and older, base-case analyses indicate RZV yields ICERs around $31,000 per QALY compared to no , reflecting offsets from reduced HZ cases, (PHN), and associated healthcare utilization s. These models incorporate direct medical s, including outpatient management estimated at $2,800–$6,000 per HZ episode, and account for RZV's higher upfront relative to unvaccinated scenarios. In contrast, analyses of the live attenuated zoster vaccine (Zostavax) have shown marginal cost-effectiveness, primarily due to substantial waning of protection over time, with effectiveness dropping to as low as 12% after 10 years against HZ with complications. Zostavax models often exceed $100,000 per QALY in scenarios assuming durations shorter than 10 years, limiting net societal value compared to RZV, which maintains higher durability. Lower historical uptake of Zostavax further diminished potential savings from averted HZ-related expenditures. Sensitivity analyses reveal that incorporating emerging evidence of RZV's associations with reduced incidence (up to 3.5 percentage points lower over 7 years) and cardiovascular events (e.g., 23% lower heart ) could substantially improve ICERs, potentially rendering cost-saving at moderate coverage levels. Standard models break even or achieve dominant (cost-saving) status at coverage rates of 30–40%, driven by herd effects and economies in preventing HZ outbreaks among older adults. Overall, RZV demonstrates favorable value in preventing an annual U.S. HZ economic burden involving millions in direct costs from complications like PHN.

Barriers to Uptake and Policy Recommendations

Despite expanded coverage, out-of-pocket costs remain a barrier for some uninsured or underinsured individuals, with the for the two-dose Shingrix series exceeding $400 as of 2024. Fears of reactogenicity, including common side effects like injection-site and , contribute to lower initiation and completion rates of the two-dose regimen, particularly among adults aged 50 and older. Provider-related hurdles, such as time constraints in assessing contraindications and perceived insufficient knowledge of zoster risk, further impede recommendations in settings. Logistical challenges, including cold-chain storage requirements and the need for reconstitution prior to administration, exacerbate implementation difficulties in community and facilities. These factors have resulted in persistently low uptake, with only about 36% of U.S. adults aged 50 years and older receiving at least one dose as of 2022 data, though rates have shown modest increases following policy changes. Policy interventions have aimed to address these barriers through enhanced subsidies and administrative simplifications. In the United States, the of 2022 eliminated out-of-pocket costs for Shingrix under starting in 2023, leading to a 46% rise in vaccinations among covered beneficiaries compared to the prior year. In the European Union, the European Medicines Agency's Committee for Medicinal Products for Human Use issued a positive opinion in October 2025 for a prefilled presentation of Shingrix, anticipated for full approval by December 2025, which eliminates reconstitution steps and reduces preparation errors in clinical settings. Evidence-based recommendations emphasize targeted implementation for high-risk groups, such as adults over 70 years with comorbidities, alongside integration into routine elderly protocols during annual wellness visits to leverage existing . Broadening provider education on zoster and logistics, combined with incentives for completion of the two-dose series in institutional settings like nursing homes, could further elevate coverage without relying on mandates.

Controversies and Criticisms

Debates on Overstated Efficacy and Breakthrough Cases

Critics have argued that efficacy estimates for recombinant zoster vaccine (RZV, Shingrix), often exceeding 90% against zoster (HZ) in adults aged 50 and older, overstate real-world performance due to differences in population characteristics and follow-up duration. Real-world studies report vaccine effectiveness (VE) ranging from 70% to 76% over 4 years post-vaccination, with lower rates in subgroups such as those aged 65 and older or with comorbidities. A 2025 analysis estimated 74% VE against HZ in adults over 50, highlighting persistent gaps between controlled trial environments and broader application. Breakthrough HZ cases occur in approximately 5-10% of vaccinated individuals, particularly among frail or immunosuppressed populations where VE drops to 50-70%, as evidenced in patients with on immunomodulators. These subgroups were often underpowered or excluded from pivotal trials, leading to debates on generalizability and the need for tailored communication. Questions about waning immunity persist despite 2024-2025 long-term data showing sustained efficacy of 79-82% at 6-11 years, as early post-vaccination VE may decline more rapidly in vulnerable groups before stabilizing. Relative risk reductions in trials mask modest absolute risk reductions (ARR), typically 1-3.5% over several years given HZ's baseline incidence of 5-10 per 1,000 person-years in unvaccinated older adults, resulting in a number needed to vaccinate (NNV) of around 28 to prevent one case. For low-risk individuals, this translates to minimal absolute benefits, prompting critiques that marketing emphasizes relative metrics without contextualizing absolute gains or subgroup limitations. Similar concerns applied to Zostavax, the live-attenuated vaccine discontinued in 2020, where initial efficacy of 51-67% waned to 15-27% by years 8-10, arguably overhyped in promotions prior to Shingrix's dominance without sufficient emphasis on durability. Proponents counter that empirical data affirm RZV's superiority over Zostavax and , with VE holding against severe outcomes like , underscoring the importance of on these limits rather than dismissal. Nonetheless, trial-to-real-world discrepancies necessitate ongoing surveillance to refine expectations, especially as uptake expands beyond trial cohorts. In the United States, legal challenges primarily targeted Zostavax, the live-attenuated herpes zoster vaccine manufactured by Merck & Co., with plaintiffs alleging that the vaccine disseminated its attenuated varicella-zoster virus, causing shingles outbreaks or severe complications including vision and hearing loss. These claims, filed predominantly before 2020, were consolidated into Multidistrict Litigation (MDL) No. 2848 in the U.S. District Court for the Eastern District of Pennsylvania, where over 1,000 cases asserted failure-to-warn and defective design defects. The MDL court issued a Lone Pine order in 2021 requiring plaintiffs to submit evidence, such as PCR testing distinguishing vaccine-strain from wild-type virus, to establish specific causation for alleged cases. In December 2022, this resulted in the dismissal of 1,189 cases for non-compliance and insufficient proof linking injuries to the vaccine. The U.S. Court of Appeals for the Third Circuit affirmed these dismissals in July 2024, ruling that the district court did not abuse its discretion in enforcing evidentiary standards to weed out . As of September 2025, Merck continued defending a reduced number of cases, approximately 60, with no reported large-scale settlements or liability findings establishing widespread vaccine-induced harm. For Shingrix, the recombinant zoster vaccine by GlaxoSmithKline, alleged harms including claims of induced or worsened zoster have surfaced in isolated solicitations by law firms as of 2025, but no multidistrict litigation or significant court precedents have materialized. The U.S. (FDA) and Centers for Disease Control and Prevention (CDC) have upheld both vaccines' profiles, stating that post-licensure data confirm benefits in preventing zoster and its complications exceed known risks, with no evidence warranting withdrawal or broad causal attributions beyond rare, monitored events. These regulatory assessments, informed by including analyses, contrast with litigant assertions by emphasizing epidemiological lack of excess incidence tied to vaccination.

Public Skepticism and Vaccine Hesitancy Factors

Public skepticism toward the zoster vaccine, particularly recombinant zoster vaccine (RZV or Shingrix), stems primarily from the perceptual imbalance between visible adverse reactions and the abstract prevention of herpes zoster (). Clinical trials and post-marketing surveillance document common side effects such as injection-site pain, , and affecting over 50% of recipients, often lasting days and prompting self-reports that amplify perceived risks. In contrast, vaccine benefits manifest as reduced incidence, which remains probabilistic and unobservable in individuals, leading to cognitive biases favoring immediate, tangible harms over delayed, statistical gains. Surveys reveal hesitancy rates contributing to low uptake, with U.S. coverage for the two-dose RZV series at just 18.1% among adults aged ≥50 years as of 2022, despite recommendations since 2017. A of global studies reported pooled willingness at 55.74%, with unwillingness driven by safety concerns (e.g., fears of rare severe events), low perceived disease risk, and financial barriers like out-of-pocket costs exceeding $300 per series before subsidies. In regions without universal coverage, such as pre-2023 plans, cost deterred 20-30% of eligible adults, compounded by inadequate provider counseling on severity. Anti-vaccination narratives on further erode trust by emphasizing outlier "vaccine injury" claims, despite empirical rarity of serious adverse events (e.g., Guillain-Barré at <1 per million doses), fostering broader distrust in pharmaceutical motives amid high-profit margins for RZV. Hesitancy correlates with sociodemographic factors, including lower and levels, which exacerbate about and necessity. In , where awareness remains low, hesitancy exceeds 60% among middle-aged and older adults due to complacency and information gaps, mirroring global patterns where trusted sources like physicians under-recommend the . Political affiliations influence perceptions unevenly; while general vaccine skepticism aligns more with conservative distrust of profit-driven pharma entities, zoster-specific uptake shows less partisan divergence than vaccines, though right-leaning groups express greater wariness of mandates and over-reliance on assurances. Transparent dissemination of real-world , such as VAERS-confirmed low severe event rates, could counter overconfidence in institutional narratives by highlighting causal over anecdotal amplification.

History and Regulatory Developments

Early Development and Zostavax Introduction (2000s)

The Oka strain of live attenuated varicella-zoster virus (VZV), originally developed by in during the early 1970s through of a wild-type isolate, formed the basis for both varicella and subsequent zoster vaccines. Initially licensed in the United States as Varivax in 1995 for preventing primary varicella, the strain was adapted by Merck for zoster prevention via a higher-potency formulation in Zostavax, containing approximately 14 times the plaque-forming units (about 50,000–60,000 PFU per dose) compared to Varivax to enhance against VZV reactivation in latently infected adults. This evolution addressed the rationale that boosting waning immunity in older individuals could mitigate herpes zoster risk, given VZV's lifelong latency post-primary infection. The cornerstone trial for Zostavax was the Shingles Prevention Study (SPS), a multicenter, randomized, double-blind, placebo-controlled phase 3 trial sponsored by Merck and conducted primarily through the U.S. Department of from December 1998 to around 2003, enrolling 38,546 immunocompetent participants aged 60 years or older without prior zoster history. Published in the New England Journal of Medicine on June 2, 2005, the SPS reported overall of 51% (95% CI, 44 to 58) against zoster incidence and 67% (95% CI, 55 to 76) against over a mean follow-up of 3.1 years, with the vaccine burden of illness due to zoster reduced by 61%. Subgroup analyses revealed higher efficacy in younger elderly participants (64% for zoster in ages 60–69 versus 38% in ages ≥70), underscoring immune senescence challenges in advanced age. Following SPS data, the U.S. approved Zostavax on May 25, 2006, for herpes zoster prevention in adults aged 60 and older, with a recommended single subcutaneous dose. The authorized it on May 19, 2006, for individuals aged 50 and older to prevent zoster and , enabling initial availability across EU member states including the by 2006–2007, though routine national recommendations varied and the UK's targeted program launched later in 2013. Early post-approval observations confirmed SPS findings on modest in the oldest cohorts (e.g., <40% in some ≥80-year analyses), alongside live-virus constraints like in immunocompromised patients, spurring late-2000s explorations of potency enhancements or non-live alternatives to improve in frail elderly populations.

Shingrix Advancement and Zostavax Discontinuation (2010s–2020s)

GlaxoSmithKline (GSK) advanced the development of Shingrix, a recombinant zoster vaccine (RZV), through pivotal phase 3 trials in the early 2010s, including ZOE-50 for adults aged 50 years and older and ZOE-70 for those aged 70 years and older. These trials, which enrolled participants starting around 2011 and reported primary results by 2015–2016, demonstrated vaccine efficacy exceeding 90% against herpes zoster across age groups, surpassing the approximately 50% efficacy of the live attenuated Zostavax. The U.S. Food and Drug Administration (FDA) approved Shingrix on October 20, 2017, for prevention of shingles in adults aged 50 years and older, administered as a two-dose intramuscular series. The Advisory Committee on Immunization Practices (ACIP) recommended Shingrix in October 2017, explicitly preferring it over Zostavax for immunocompetent adults aged 50 years and older due to its higher and more durable efficacy, despite potentially more frequent local reactogenicity. This preference reflected data showing Shingrix's superiority in preventing and , prompting a market shift as healthcare providers prioritized the non-live vaccine, which avoided contraindications in immunocompromised individuals. Merck discontinued Zostavax in the effective November 18, 2020, citing reduced demand amid the dominance of and manufacturing challenges, alongside Zostavax's waning protection over time documented in observational studies. The phase-out was driven by Shingrix's evidence-based advantages, including sustained efficacy without the limitations of live-virus attenuation that contributed to Zostavax's inferior performance in older adults. Globally, Zostavax discontinuations accelerated in the early 2020s, with Merck halting supply in markets such as by 2023 and broader withdrawal efforts by 2024, aligning with regulatory preferences for recombinant alternatives. This transition facilitated a surge in U.S. herpes zoster vaccination coverage, rising to approximately 36% for at least one dose among adults aged 50 years and older by 2022, reflecting increased adoption of Shingrix post-approval and policy endorsements.

Recent Approvals and Research Milestones (2020–2025)

In October 2025, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a new prefilled presentation of Shingrix, GlaxoSmithKline's recombinant zoster vaccine (RZV), simplifying administration by eliminating the need for reconstitution. approval is anticipated by December 2025, building on Shingrix's existing authorization for preventing herpes zoster (HZ) and post-herpetic neuralgia in adults aged 50 and older. The final analysis of the ZOE-LTFU study, published in May 2025, confirmed sustained efficacy of Shingrix up to 11 years post-vaccination, with vaccine effectiveness against HZ at 79.7% (95% CI: 73.7–84.6%) in adults aged 50 and older and minimal waning over time across age groups. This long-term follow-up of phase 3 trials demonstrated persistent protection against HZ-related complications, supporting recommendations for single-series vaccination without routine boosters as of 2025. Research milestones in 2025 included a study in Clinical Infectious Diseases reporting 72.9% (95% CI: 67.0–77.8%) adjusted effectiveness of two RZV doses against herpes zoster ophthalmicus in adults aged 50 and older, highlighting benefits beyond general HZ prevention. A presented at the 2025 Congress found herpes zoster vaccination associated with an 18% relative risk reduction in composite cardiovascular events, including and , based on pooled data from multiple observational studies. Similarly, a in indicated that zoster vaccination reduced new diagnoses by 3.5 percentage points over seven years of follow-up, suggesting potential neuroprotective effects linked to preventing viral reactivation. Ongoing clinical trials as of 2025 explore Shingrix efficacy in adults under 50 years, particularly immunocompromised populations, and assess durability beyond 11 years to inform potential booster strategies, though no additional doses are currently recommended. No new competing zoster vaccines have gained regulatory approval by October 2025, with investigational candidates like Dynavax's Z-1018 in early-phase testing showing preliminary immunogenicity comparable to Shingrix but remaining pre-approval.

References

  1. https://www.cdc.gov/shingles/hcp/clinical-overview/index.html
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC6590925/
  3. https://www.fda.gov/files/vaccines%2C%2520blood%2520&%2520biologics/published/Package-Insert-SHINGRIX.pdf
  4. https://www.cdc.gov/shingles/vaccines/index.html
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7336348/
  6. https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix
  7. https://academic.oup.com/cid/article/73/6/941/6134290
  8. https://www.cdc.gov/vaccine-safety/vaccines/shingles-herpes.html
  9. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-warning-about-guillain-barre-syndrome-gbs-be-included-prescribing-information-shingrix
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC9071519/
  11. https://health.clevelandclinic.org/can-you-get-shingles-if-you-havent-had-chickenpox
  12. https://journals.asm.org/doi/10.1128/jvi.02592-07
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC4066823/
  14. https://www.cdc.gov/shingles/data-research/index.html
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6984676/
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC5036669/
  17. https://www.neurology.org/doi/10.1212/WNL.0000000000002808
  18. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-014-0556-6
  19. https://pmc.ncbi.nlm.nih.gov/articles/PMC12538380/
  20. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00046/full
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC4014857/
  22. https://academic.oup.com/ofid/article/12/1/ofae738/7929831
  23. https://www.aafp.org/pubs/afp/issues/2017/1115/p656.html
  24. https://www.nejm.org/doi/full/10.1056/NEJMcp1302674
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC10583132/
  26. https://tkl.uptodate.com/contents/vaccination-for-the-prevention-of-shingles-herpes-zoster-in-adults/print
  27. https://www.fda.gov/files/vaccines%252C%2520blood%2520%2526%2520biologics/published/Package-Insert-SHINGRIX.pdf
  28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6102791/
  29. https://www.ema.europa.eu/en/documents/product-information/shingrix-epar-product-information_en.pdf
  30. https://www.drugs.com/history/shingrix.html
  31. https://www.ema.europa.eu/en/medicines/human/EPAR/shingrix
  32. https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html
  33. https://divisionofresearch.kaiserpermanente.org/waning-original-shingles-vaccine/
  34. https://www.pharmavoice.com/news/gsk-shingles-vaccine-shingrix-curevo/710619/
  35. https://m.facebook.com/CDC/photos/zostavax-will-no-longer-be-sold-in-the-united-states-as-of-july-1-2020-some-phar/10158111614416026/?locale=ms_MY
  36. https://www.ema.europa.eu/en/medicines/human/EPAR/zostavax
  37. https://pmc.ncbi.nlm.nih.gov/articles/PMC10995133/
  38. https://www.fda.gov/media/82524/download
  39. https://archive.cdc.gov/www_cdc_gov/vaccines/vpd/shingles/hcp/zostavax/recommendations.html
  40. https://www.medsafe.govt.nz/profs/PUArticles/September2017/Zostavax.htm
  41. https://pmc.ncbi.nlm.nih.gov/articles/PMC2679676/
  42. https://www.fda.gov/vaccines-blood-biologics/vaccines/zostavax-herpes-zoster-vaccine-questions-and-answers
  43. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/varicella-zoster-vaccine
  44. https://www.drugs.com/history/zostavax.html
  45. https://carlsibicky.wordpress.com/2022/04/03/why-was-zostavax-discontinued-in-the-u-s/
  46. https://www.nejm.org/doi/full/10.1056/NEJMoa1501184
  47. https://pubmed.ncbi.nlm.nih.gov/27626517/
  48. https://shingrixhcp.com/efficacy-safety/efficacy-data/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC10026829/
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC3083261/
  51. https://www.sciencedirect.com/science/article/pii/S1684118224001087
  52. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00173-7/fulltext
  53. https://www.gsk.com/en-gb/media/press-releases/new-long-term-data-show-shingrix-continues-to-provide-high-protection-against-shingles-in-adults-aged-50-and-over-for-more-than-a-decade/
  54. https://www.bmj.com/content/383/bmj-2023-076321
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC6018833/
  56. https://www.nature.com/articles/s41541-022-00467-z
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC7925171/
  58. https://www.healio.com/news/infectious-disease/20200424/shingrix-induces-persistent-immune-responses-in-older-adults-regardless-of-zostavax-dose
  59. https://www.sciencedirect.com/science/article/pii/S2590136223001389
  60. https://www.acpjournals.org/doi/10.7326/ANNALS-24-02409
  61. https://www.cidrap.umn.edu/varicella/study-estimates-74-efficacy-shingles-vaccine-patients-over-50
  62. https://pubmed.ncbi.nlm.nih.gov/33197294/
  63. https://academic.oup.com/jid/article-pdf/218/suppl_2/S63/25823584/jiy263.pdf
  64. https://www.sciencedirect.com/science/article/pii/S2666756822000393
  65. https://www.cdc.gov/nchs/products/databriefs/db370.htm
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC10653743/
  67. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaf395/8230148
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC8807177/
  69. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf329/8171839
  70. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-notes.html
  71. https://www.cdc.gov/acip-recs/hcp/vaccine-specific/shingles.html
  72. https://archive.cdc.gov/www_cdc_gov/vaccines/vpd/shingles/hcp/zostavax/hcp-vax-recs.html
  73. https://lupusuk.org.uk/2025/09/01/shingles-vaccine-guideline-update/
  74. https://www.cdc.gov/shingles/hcp/vaccine-considerations/immunocompromised-adults.html
  75. https://shingrixhcp.com/home-ic/who-to-vaccinate/cdc-recommendations/
  76. https://shingrixhcp.com/home-ic/immunogenicity-data/post-autologous-hematopoietic-stem-cell-transplant/
  77. https://pmc.ncbi.nlm.nih.gov/articles/PMC8828160/
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC6312897/
  79. https://pmc.ncbi.nlm.nih.gov/articles/PMC10751080/
  80. https://ncirs.org.au/zoster-shingles/zoster-shingles-vaccine-frequently-asked-questions-faqs
  81. https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-receives-positive-chmp-opinion/
  82. https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-shingrix-in-a-prefilled-syringe-presentation/
  83. https://www.fda.gov/media/119879/download
  84. https://www.cdc.gov/pinkbook/hcp/table-of-contents/chapter-23-zoster.html
  85. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2785607
  86. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561433/
  87. https://www.drugs.com/sfx/zostavax-side-effects.html
  88. https://www.mayoclinic.org/drugs-supplements/zoster-vaccine-live-subcutaneous-route/description/drg-20444512
  89. https://www.bmj.com/content/363/bmj.k4029
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC6201212/
  91. https://pmc.ncbi.nlm.nih.gov/articles/PMC3967828/
  92. https://academic.oup.com/jid/article/224/Supplement_4/S429/6378089
  93. https://www.foundationforpn.org/peripheral-neuropathy-qa-flu-and-shingles-shots/
  94. https://www.immunize.org/ask-experts/topic/zoster/contraindications-precautions-zoster-shingles/
  95. https://www.cdc.gov/vaccines/hcp/imz-best-practices/contraindications-precautions.html
  96. https://dph.georgia.gov/document/document/herpes-zoster-zos/download
  97. https://shingrixhcp.com/recommend-administer/coadministration/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC12258169/
  99. https://shingrixhcp.com/content/dam/brs-pharma-us/shingrix-hcp/en_us/home/5-0-resources/pdf/SHINGRIX%2520Coadministration%2520Guide.pdf
  100. https://archive.cdc.gov/www_cdc_gov/vaccines/vpd/shingles/public/zostavax/index.html
  101. https://ca.gsk.com/media/haune4k3/shingrix-pi-en.pdf
  102. https://pubmed.ncbi.nlm.nih.gov/31003070/
  103. https://www.jci.org/articles/view/172634
  104. https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF
  105. https://archive.cdc.gov/www_cdc_gov/vaccines/vpd/shingles/hcp/zostavax/about-vaccine.html
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC6151076/
  107. https://pmc.ncbi.nlm.nih.gov/articles/PMC4559191/
  108. https://pmc.ncbi.nlm.nih.gov/articles/PMC6605864/
  109. https://www.nature.com/articles/s41586-025-08800-x
  110. https://www.nature.com/articles/s41591-024-03201-5
  111. https://www.ox.ac.uk/news/2024-07-25-new-shingles-vaccine-could-reduce-risk-dementia
  112. https://www.cidrap.umn.edu/adult-non-flu-vaccines/shingles-vaccine-tied-significant-reductions-risk-dementia-heart-disease-and
  113. https://www.cell.com/trends/neurosciences/abstract/S0166-2236%2825%2900145-6
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC12198376/
  115. https://alzdiscovery.org/uploads/cognitive_vitality_media/Shingles_vaccine.pdf
  116. https://www.escardio.org/The-ESC/Press-Office/Press-releases/New-systematic-review-and-meta-analysis-shows-an-association-between-shingles-vaccination-and-lower-risk-of-heart-attack-and-stroke
  117. https://www.escardio.org/The-ESC/Press-Office/Press-releases/shingles-vaccine-lowers-the-risk-of-heart-disease-for-up-to-eight-years
  118. https://pmc.ncbi.nlm.nih.gov/articles/PMC10974237/
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC11836834/
  120. https://www.healio.com/news/infectious-disease/20251020/shingles-vaccination-lowers-risk-for-heart-disease-dementia-death
  121. https://www.jacc.org/doi/10.1016/j.jacc.2025.07.003
  122. https://jamanetwork.com/journals/jama/article-abstract/2839210
  123. https://pmc.ncbi.nlm.nih.gov/articles/PMC12023514/
  124. https://link.springer.com/article/10.1007/s41669-025-00604-z
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC9309417/
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC4514227/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC4186035/
  128. https://www.cnn.com/2025/05/09/health/shingles-heart-disease-vaccine-shots-wellness
  129. https://bmchealthservres.biomedcentral.com/articles/10.1186/s12913-025-12550-x
  130. https://www.healthaffairs.org/doi/10.1377/hlthaff.2016.0462
  131. https://www.goodrx.com/conditions/shingles/shingles-vaccine-cost-shingrix
  132. https://www.sciencedirect.com/science/article/pii/S0264410X25007625
  133. https://pubmed.ncbi.nlm.nih.gov/40249278/
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC11350440/
  135. https://www.cdc.gov/adultvaxview/publications-resources/adult-vaccination-coverage-2022.html
  136. https://schaeffer.usc.edu/research/shingles-vaccine-uptake-increased-after-ira-removes-opc/
  137. https://www.nfid.org/resource/call-to-action-strategies-to-improve-adult-immunization-in-the-us/
  138. https://pmc.ncbi.nlm.nih.gov/articles/PMC5755371/
  139. https://pubmed.ncbi.nlm.nih.gov/33580242/
  140. https://divisionofresearch.kaiserpermanente.org/shingles-vaccine-strong-effectiveness/
  141. https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2327145
  142. https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-025-03565-0
  143. https://pmc.ncbi.nlm.nih.gov/articles/PMC12085024/
  144. https://www.sciencedirect.com/science/article/pii/S2589537025001737
  145. https://www.bmj.com/content/363/bmj.k4029/rr-3
  146. https://database.inahta.org/article/22814
  147. https://www.neuralit.com/mass-tort-news/zostavax-shingles-vaccine-fades-after-10-years-study
  148. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf473/8250066
  149. https://www.millerandzois.com/products-liability/drugs/zostavax/
  150. https://www.njcourts.gov/multicounty-litigation/zostavax/case-information
  151. https://www.faegredrinker.com/en/insights/publications/2022/12/failure-to-comply-with-lone-pine-order-results-in-dismissal-of-over-1000-cases-in-zostavax-mdl
  152. https://www2.ca3.uscourts.gov/opinarch/231032np.pdf
  153. https://www.nvic.org/disease-vaccine/shingles/vaccine-injury
  154. https://pmc.ncbi.nlm.nih.gov/articles/PMC11788766/
  155. https://shingrixhcp.com/home-ic/efficacy-safety/adverse-reactions/
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC11303218/
  157. https://pmc.ncbi.nlm.nih.gov/articles/PMC10037179/
  158. https://www.tandfonline.com/doi/full/10.1080/21645515.2024.2317595
  159. https://www.ssph-journal.org/journals/public-health-reviews/articles/10.3389/phrs.2024.1606679/full
  160. https://www.sciencedirect.com/science/article/pii/S0196655325005036
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC11402811/
  162. https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2563960
  163. https://www.pharmacytimes.com/view/survey-identifies-factors-in-herpes-zoster-vaccine-hesitancy-among-older-adults
  164. https://www.mdpi.com/2076-393X/13/8/843
  165. https://pmc.ncbi.nlm.nih.gov/articles/PMC5942150/
  166. https://www.nejm.org/doi/full/10.1056/NEJMoa051016
  167. https://purplebooksearch.fda.gov/productdetails?query=125123
  168. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2010.03023.x
  169. https://www.hhs.gov/sites/default/files/2018-9-13-nvac-friedland-journeyofnewshinglesvaccine.pdf
  170. https://www.fda.gov/files/vaccines%252C%2520blood%2520&%2520biologics/published/October-20--2017-Summary-Basis-for-Regulatory-Action---SHINGRIX.pdf
  171. https://www.izsummitpartners.org/content/uploads/2018/02/ACIP-Recs-Herpes-Zoster-NAICP-Feb2018-Dooling.pdf
  172. https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-8-herpes-zoster-%28shingles%29-vaccine.html
  173. https://www.pharmajournalist.com/ema-backs-approval-of-gsks-shingrix-in-new-prefilled-syringe-format/
  174. https://pubmed.ncbi.nlm.nih.gov/40630610/
  175. https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaf440/8229580
  176. https://clinicaltrials.gov/study/NCT02723773
  177. https://www.reuters.com/business/healthcare-pharmaceuticals/dynavaxs-shingles-vaccine-shows-similar-immune-response-gsks-shot-study-2025-08-21/
Add your contribution
Related Hubs
User Avatar
No comments yet.